NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON

Vendor Intelligence Report: HkRoids

Published 12 Nov 2026. 35-page investigative report on who is behind HkRoids: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

HkRoids is a product-specific vendor, not a uniform good-or-bad story. Across 83 Finnrick lab tests, the record is 55 pass / 27 fail, an overall pass rate of 66%. GHK-Cu is the clearest strong line; Retatrutide is a conditional positive; Tirzepatide tests comparatively well but carries a separate batch-identity caution; KPV is the standout weak line. The full report shows how ratings compress when purity and fill thresholds tighten.

The public operating trail does not support the listed US signal as a complete identity story. A legacy Hong Kong Shijingu layer and current Wuhan Jinsai-linked web properties point to China/Hong Kong operations, while the current legal seller and ultimate beneficial owner remain unresolved. Public sources identify sales and forum administration more clearly than quality-release authority; the report treats that as an oversight-scope limitation, not proof that technical staff do not exist.

The sharpest non-testing finding is documentation integrity. HkRoids publishes genuine, verifiable Testides HPLC records beside separate Testides-branded endotoxin images for the same sample family that do not verify in Testides' lookup; one BPC/TB image also matches an image circulating in another vendor's PDF. The report then follows the buyer-facing consequences: hidden representative cards in the public page code, official anti-impersonation messaging, clone-site exposure, manual payment instructions, a PayPal surcharge, and limited refund leverage after tracking.

Inside the full report:

  • Per-product Finnrick pass/fail analysis and methodology-divergence charts for all 11 HkRoids products
  • Testides lookup captures comparing valid HPLC reports with non-verifying endotoxin report numbers
  • Side-by-side image comparison of the BPC/TB endotoxin artifact and its cross-vendor appearance
  • Hong Kong Shijingu, Wuhan Jinsai, Alab Supplies and HKR Novalix operating-footprint analysis
  • Official-channel, hidden rep-roster, clone-site and payment-flow exhibits for buyer verification

Risk assessment

  • Documentation-integrity risk — high: HkRoids publishes three Testides-branded endotoxin reports for Retatrutide, BPC-157/TB-500 and MOTS-c whose report numbers Testides does not verify, despite verified companion HPLC reports.
  • Product-specific quality risk — high: Finnrick record is strong for GHK-Cu, Retatrutide and Tirzepatide but weak for KPV (20.15%), CJC-1295 (32.26%), MOTS-c (36.45%) and borderline Tesamorelin (50.94%).
  • Copycat and official-channel confusion risk — high: Vendor documents fake sites copying reports/content; public HTML exposes 39 rep cards, and Novelle Peptid is an unresolved HkRoids-style clone.
  • Payment, refund and customs-recourse risk — medium: Checkout offered PayPal with 5% fee or Bitcoin/USDT, post-order instructions, no named legal seller; refunds end after tracking and forum posts cite China-border customs delays.
  • Counterparty and ownership opacity risk — medium: Legacy Shijingu and current Wuhan Jinsai links support China/Hong Kong operations, but UBO and current legal seller were not identified; no US entity was found.